HFpEF Drug Discovery and Development Summit 2022 | Digital Event

Memo

Taking place online, the HFpEF Drug Discovery and Development Summit 2022 is the first and only devoted meeting uniting large pharma, biotech, and pioneering academics under the mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat HFpEF, an extremely common heart failure with a huge unmet medical need. Join 80+ experts at this ground-breaking forum with the likes of AstraZeneca, Eli Lilly, Bayer, Amgen, Novartis, and many more sharing state-of-the-art insights and expertise in heart failure. Covering topics including specific and applied drug development hurdles with inadequate successful treatments, such as the translational challenges between phases of pre-clinical and clinical trials, this is a conversation not to miss. Attending this summit will equip you with the information and partnerships to succeed and translate drug candidates into human clinical trials, whilst optimizing your clinical development process itself to evade further clinical failures. URLs:Tickets: https://go.evvnt.com/878934-2?pid=5569 Brochure: https://go.evvnt.com/878934-3?pid=5569  Date and Time: On Tue, Jan 25, 22 ( 8:00 AM) - Thu, Jan 27, 22 ( 7:00 PM) Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Conference + 1 Workshop - Industry: USD 2448.00,Conference Only - Industry: USD 2099.00,Conference + 1 Workshop - Academic: USD 2198.00,Conference Only - Academic: USD 1899.00,Conference + 1 Workshop - Solution Provider: USD 3048.00,Conference Only - Solution Provider: USD 2649.00 Speakers: Samir Ounzain, Cofounder, HAYA Therapeutics, Sean Bedingfield, Research Engineer - Drug Delivery, Eli Lilly Company – New Therapeutic Modalities, Sheldon Litwin, Board-certified in general cardiology, Medical University South Carolina, Sunjay Kaushal, Founder and Chief Medical Officer, NeoProgen Inc., Uli Breodl, Head of Global Clinical Development and Operations Boehringer Ingelheim, Georgios, Karamanlidis Senior Scientist, Amgen, Mark Kowala, President, Cardiobiopharma LLC, Ola Vedin, Global Medical Director Heart Failure, Boehringer Ingelheim, Rachel Roth, Flach Senior Principal Scientist, Pfizer, Regina Danielson, Senior Vice President and Head of Research and Early Development, AstraZeneca, Richard Nkulikiyinka, Vice President, Head of Therapeutic Area Cardiology and Nephrology, Bayer, Robert Unwin, Chief Scientist, AstraZeneca, Andreas Busch, Chief Scientific Officer, Cyclerion Therapeutics, Danilo Norata, Giuseppe Professor of Pharmacology, University of Milan, Gavin Oudit, Cardiologist and Clinician-Scientist, Mazankowski Alberta Heart Institute, Javed Butler, Director of Cardiovascular Medicine, Stony Brook Medicine, Jyothis George, Vice President - Clinical Development, Medical Affairs and Regulatory, Novo Nordisk, Li-Ming Gan, Vice President and Global Head of Early Clinical Development and CVRM, AstraZeneca, Qing-Dong, Wang Senior Principal Scientist, AstraZeneca, Flora Sam, Senior Medical Fellow, Early Phase Cardiovascular Research – Diabetes and Complications Advanced Heart Failure Cardiologist and Physician-scientist, Eli Lilly